Condition

Neoplasm Metastasis clinical trials and research

• 16Clinical trials
• 35Countries

Newest Neoplasm Metastasis clinical trials

All recruiting trials (16)

• Pluvicto real-world use in metastatic castration-resistant prostate cancer

  This real-world study tests how well Pluvicto works in men with metastatic castration-resistant prostate cancer in the US and Germany.

  Recruiting Novartis · East Hanover, New Jersey · NCT07697989

• Vepugratinib with enfortumab vedotin and pembrolizumab for FGFR3‑altered advanced urothelial cancer

  This trial tests whether adding vepugratinib to enfortumab vedotin and pembrolizumab helps people with advanced or metastatic urothelial (bladder) cancer who have an FGFR3 genetic change, compared with placebo.

  Recruiting at 129 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 275 other locations · NCT07218380

• Sofetabart Mipitecan (LY4170156) versus standard chemotherapy for platinum-resistant and platinum-sensitive high-grade ovarian, fallopian tube, and primary peritoneal cancer

  This trial tests whether the targeted drug Sofetabart Mipitecan can better shrink tumors or delay progression than standard chemotherapies for people with platinum-resistant or platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 212 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 263 other locations · NCT07213804

• Tersolisib plus standard anti-cancer medicines for advanced HR+/HER2- breast cancer with a PIK3CA change

  This trial tests whether adding tersolisib to standard first-line anti-cancer medicines helps people with advanced hormone receptor–positive, HER2‑negative breast cancer that has a PIK3CA mutation.

  Recruiting at 179 sites Phase 3 Eli Lilly and Company · Anchorage, Alaska and 363 other locations · NCT07174336

• LY4257496 for GRPR-positive advanced breast, colorectal, prostate, and endometrial cancer (OMNIRAY)

  This Phase 1 test tries LY4257496, with GRPR imaging using LY4257529 and sometimes standard treatments, to see if it is safe and helps people with GRPR-positive advanced breast, colorectal, prostate, or endometrial cancer.

  Recruiting at 15 sites Phase 1 Eli Lilly and Company · Duarte, California and 32 other locations · NCT07114601

• LY4175408 for selected advanced lung, endometrial, and triple‑negative breast cancers

  This trial tests an experimental drug called LY4175408 to see if it is safe and works for people with advanced or metastatic non‑small cell or small cell lung cancer, endometrial cancer, or triple‑negative breast cancer.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Stanford, California and 26 other locations · NCT07046923

• Zanzalintinib with pembrolizumab and cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial tests whether adding the oral drug zanzalintinib to pembrolizumab and cetuximab is safe and finds the best dose for adults with recurrent or metastatic head and neck squamous cell cancer.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT06912087

• Using cadonilimab with chemotherapy and radiation for advanced endometrial cancer

  This study is testing if adding cadonilimab to chemotherapy and radiation can help people with advanced endometrial cancer live longer and feel better.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06532539

• Combining Olomorasib and Pembrolizumab for Advanced KRAS G12C-Mutant Lung Cancer

  This study is testing if a new drug combined with Pembrolizumab can help people with advanced lung cancer that has a specific genetic mutation feel better and live longer compared to standard treatments.

  Recruiting at 413 sites Phase 3 Eli Lilly and Company · Huntsville, Alabama and 414 other locations · NCT06119581

• Understanding factors affecting prostate cancer progression

  This study is trying to find out what factors affect how prostate cancer grows in different people to help improve treatment and prevention for those at higher risk.

  Recruiting Centre Hospitalier Universitaire de la Guadeloupe · Rennes, Ille-et-Vilaine and 1 other locations · NCT06046131

• Evaluating LOXO-435 for treating cancer with FGFR3 gene changes

  This study is testing a new cancer drug called LOXO-435 to see if it can safely help people with advanced tumors that have changes in the FGFR3 gene, either on its own or with standard treatments.

  Recruiting at 82 sites Phase 1 Eli Lilly and Company · Tucson, Arizona and 82 other locations · NCT05614739

• Observing patient outcomes in breast cancer patients treated with trastuzumab deruxtecan

  This study is looking to see how well trastuzumab deruxtecan works for people with certain types of advanced breast cancer and how they feel about their treatment.

  Recruiting at 105 sites AstraZeneca · Amberg and 108 other locations · NCT05573893

• Combining laser treatment and radiosurgery for spinal tumors

  This study is testing if using both laser treatment and targeted radiation can help people with spinal tumors feel better and improve their quality of life compared to just using radiation alone.

  Recruiting Henry Ford Health System · Detroit, Michigan · NCT05023772

• Testing zongertinib for advanced cancer with HER2 gene changes

  This study is testing a new drug called zongertinib to see if it can safely shrink tumors in adults with advanced cancer that have changes in the HER2 gene.

  Recruiting at 34 sites Phase 1 Boehringer Ingelheim · Birmingham, Alabama and 84 other locations · NCT04886804

• Collecting data on patients with bone metastases treated for fractures

  This study is trying to see how different surgical treatments for bone fractures in cancer patients affect their recovery and survival.

  Recruiting Istituto Ortopedico Rizzoli · Bologna, Bologna · NCT03416959

• Second-line FOLFIRI +/- Bevacizumab vs Irinotecan +/- Bevacizumab in Metastatic Colorectal Cancer

  This trial tests whether a second-line FOLFIRI-based regimen with or without Bevacizumab is as good as Irinotecan-based therapy with or without Bevacizumab for patients with metastatic colorectal cancer.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT03303495

Related topics

Quick answers

How many Neoplasm Metastasis clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 35 countries. The most sites are in United States (11 trials), China (10 trials), France (9 trials), Germany (8 trials), Japan (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 1: 5, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →